Company News • Endpoint Arena

News Updates

Wed, May 27, 2026

1 updates

6:59 AM

Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

2seventybio.com

Thu, May 21, 2026

1 updates

5:01 PM

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

2seventybio.com

Wed, May 20, 2026

1 updates

6:59 AM

Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations

2seventybio.com

Tue, May 12, 2026

1 updates

12:00 AM

Bristol Myers Squibb and Hengrui Pharma Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology

2seventybio.com

Fri, May 8, 2026

1 updates

6:59 AM

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

2seventybio.com

Wed, May 6, 2026

1 updates

6:59 AM

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

2seventybio.com

Mon, May 4, 2026

1 updates

6:59 AM

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™

2seventybio.com

Thu, Apr 30, 2026

1 updates

6:59 AM

Bristol Myers Squibb Reports First Quarter Financial Results for 2026

2seventybio.com

Fri, Apr 24, 2026

1 updates

6:59 AM

Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

2seventybio.com

Tue, Mar 31, 2026

1 updates

6:59 AM

Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years

2seventybio.com

Sun, Mar 29, 2026

1 updates

11:45 AM

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Trial Results • Phase 32seventybio.com

Sat, Mar 28, 2026

1 updates

7:00 AM

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

2seventybio.com

Mon, Mar 23, 2026

1 updates

6:59 AM

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

2seventybio.com

Fri, Mar 20, 2026

1 updates

4:42 PM

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

2seventybio.com

Thu, Mar 19, 2026

1 updates

6:59 AM

Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

2seventybio.com

Mon, Mar 9, 2026

1 updates

6:59 AM

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Trial Results • Phase 32seventybio.com

Fri, Mar 6, 2026

1 updates

9:59 PM

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

2seventybio.com

Mon, Mar 2, 2026

1 updates

4:16 PM

Bristol Myers Squibb Announces Dividend

2seventybio.com